| Non-Small Cell Lung Carcinoma
Hyrnuo vs Lumakras
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Hyrnuo vs Lumakras with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLumakras has a higher rate of injection site reactions vs Hyrnuo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lumakras but not Hyrnuo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrnuo
Lumakras
At A Glance
Oral
Twice daily
HER2 kinase inhibitor
Oral
Once daily
KRAS G12C inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
- Metastasis from malignant neoplasm of colon and/or rectum
Dosing
Non-Small Cell Lung Carcinoma 20 mg orally twice daily with food until disease progression or unacceptable toxicity.
Non-Small Cell Lung Carcinoma 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily as a single agent until disease progression or unacceptable toxicity.
Metastasis from malignant neoplasm of colon and/or rectum 960 mg (three 320 mg or four 240 mg or eight 120 mg tablets) orally once daily in combination with panitumumab until disease progression or unacceptable toxicity; administer the first dose prior to the first panitumumab infusion.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, nausea
Serious Diarrhea, pneumonia, dyspnea, pleural effusion
Most common (>=20%) - NSCLC Diarrhea, musculoskeletal pain, nausea, fatigue, hepatotoxicity, cough.
Most common (>=20%) - mCRC with panitumumab Rash, dry skin, diarrhea, stomatitis, fatigue, musculoskeletal pain.
Serious Hepatotoxicity, interstitial lung disease/pneumonitis, pneumonia, diarrhea (NSCLC); sepsis, intestinal obstruction (mCRC with panitumumab).
Pharmacology
Sevabertinib is a reversible kinase inhibitor of HER2 (ERBB2) that also exhibits activity against EGFR; it inhibits HER2 phosphorylation and downstream signaling in cancer cells harboring HER2 alterations and demonstrates antitumor activity in NSCLC models with activating HER2 exon 20 mutations.
KRAS G12C inhibitor; sotorasib forms an irreversible, covalent bond with the unique cysteine of KRAS G12C, locking the protein in an inactive state that prevents downstream signaling without affecting wild-type KRAS, thereby blocking tumor cell growth and promoting apoptosis in KRAS G12C tumor cell lines.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrnuo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Lumakras
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Hyrnuo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Lumakras
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Hyrnuo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Lumakras
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrnuo.
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrnuoView full Hyrnuo profile
LumakrasView full Lumakras profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.